Toward a comprehensive solution for treating solid tumors using T-cell receptor therapy: A review.

Area of Science:

• Immunotherapy
• Oncology
• Cellular Therapy

Background:

• T-cell receptor therapy (TCR-T) has shown significant efficacy, durability, and safety in specific solid tumors.
• Existing research highlights successes in human papillomavirus-related tumors, synovial sarcoma, and melanoma.

Purpose of the Study:

• To provide comprehensive considerations for developing TCR-T therapies specifically for solid tumors.
• To review current clinical applications, advantages, and key parameters influencing TCR-T efficacy and safety in solid tumors.

Main Methods:

• Review of current literature on TCR-T clinical applications and modalities.
• Exploration of efficacy/safety parameters: avidity, pharmacokinetics/pharmacodynamics, and indications.
• Investigation of factors influencing T-cell receptor avidity: antigen selection, acquisition, optimization, and co-receptor engagement.
• Analysis of tumor antigen expression using RNA-seq datasets for broader solid tumor coverage.

Main Results:

• TCR-T therapy demonstrates potential benefits in specific solid tumor types.
• Avidity, pharmacokinetics/pharmacodynamics, and antigen selection are critical for TCR-T success in solid tumors.
• RNA-seq data analysis suggests opportunities for expanding TCR-T coverage across various solid tumors.

Conclusions:

• Careful consideration of antigen selection, T-cell receptor avidity, and pharmacokinetic/pharmacodynamic profiles is essential for successful TCR-T development in solid tumors.
• Further research into optimizing TCR-T strategies and exploring novel tumor antigens is crucial for advancing this therapy.
• TCR-T holds significant promise for treating a wider range of solid tumors with improved outcomes.